Galapagos NV (EUR)
GLPG
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range162.75 | 169.35
52-Wk Range- | -
Last Close165.55
Mkt Cap (m)10,802.89
Dividend yield-
ISINBE0003818359
Volume616,447.00
Exchange VenueAMS

Company Profile

Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

Key Information
Price/Earning63.67
Price/Book3.80
Price/Sales11.40
P/CF3.23
Rev Growth (3 year avg)86.86
EPS Growth (3 year avg)0.30
Operating Margin % 43.82
Net Margin %17.73
Return on Equity7.33
Debt/Equity0.01

Documents

Prospectus
en 15/10/2018
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.glpg.com

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)69.3739.56129.52127.09288.84844.99
Operating Income (m)-35.96-89.44-11.49-89.80-44.81370.29
Net Income (m)33.21-118.4154.01-115.70-29.26149.85
Basic EPS1.10-3.321.18-2.34-0.562.60
Avg. Diluted Shares Outstanding (m)30.1135.7045.7049.4852.1160.11
Balance Sheet
EUR201420152016201720182019
Current Assets (m)213.60374.471,007.231,197.651,328.855,865.93
Non Current Assets (m)56.8668.0476.1188.63110.65202.68
Total Assets (m)270.47442.511,083.341,286.271,439.506,068.61
Current Liabilities (m)60.3672.41103.79171.70219.91571.79
Total Liabilities (m)------
Total Equity (m)206.14365.00758.701,011.981,214.252,875.66
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)-75.56-114.59239.40-147.03-142.473,208.62
Capital Expenditure (m)-2.80-6.67-4.79-7.44-13.72-45.69
Figures are quoted in EUR unless stated otherwise
-
No change
165.55
Last Price